Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3819679 | 0.93 | NPC1 (0.39) | NPC1MAPTKMT2ASMN1; SMN2PKM | |
| SCHEMBL3812795 | 0.92 | NPC1 (0.38) | NPC1MAPTKMT2ASMN1; SMN2PKM | |
| SCHEMBL3820867 | 0.92 | NPC1 (0.42) | NPC1MAPTKMT2ASMN1; SMN2PKM | |
| SCHEMBL4389693 | 0.91 | MCHR1 (0.36) | NPC1MAPTKMT2ASMN1; SMN2PKM | |
| SCHEMBL3820094 | 0.91 | KMT2A (0.39) | NPC1KMT2ARAB9AADORA3NAMPT | |
| SCHEMBL3822155 | 0.91 | RET (0.43) | HDAC3ALDH1A1HPGDKDM4ENAMPT | |
| SCHEMBL3814274 | 0.90 | RAB9A (0.44) | NPC1MAPTKMT2ASMN1; SMN2PKM | |
| SCHEMBL3820791 | 0.88 | KCNQ3 (0.38) | KMT2AADORA3NAMPTMAPK1EGLN1 | |
| SCHEMBL3813353 | 0.88 | MAPT (0.45) | NPC1MAPTKMT2ASMN1; SMN2PKM | |
| SCHEMBL4393766 | 0.86 | ALDH1A1 (0.38) | NPC1MAPTKMT2ASMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306100-A1 | METHODS OF TREATING SCHIZOPHRENIA | LEXICON PHARMACEUTICALS, INC. | 2009-12-10 | — | — | US | disclosed |
| EP-2089018-A2 | METHODS OF TREATING COGNITIVE IMPAIRMENT AND DEMENTIA | Lexicon Pharmaceuticals, Inc. (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20080153811-A1 | methods for treating, managing and preventing cognitive impairment associated with various diseases and disorders, age-associated memory impairment, and dementia. | LEXICON PHARMACEUTICALS, INC. | 2008-06-26 | — | — | US | disclosed |
| WO-2008067121-A2 | METHODS OF TREATING COGNITIVE IMPAIRMENT AND DEMENTIA | LEXICON PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| US-20070049608-A1 | Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. | 2007-03-01 | — | — | US | disclosed |
| WO-2006124897-A2 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITION | LEXICON GENETICS INCORPORATED (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060258691-A1 | Methods and compositions for improving cognition | LEXICON PHARMACEUTICALS, INC. | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153811-A1 | methods for treating, managing and preventing cognitive impairment associated with various diseases and disorders, age-associated memory impairment, and dementia. | CHAT, PSEN2, PSEN1 | NPC1 76/4885MAPT 7/4885KMT2A 651/4885 |
| US-20090306100-A1 | METHODS OF TREATING SCHIZOPHRENIA | CHAT, GAP43, GRIN2A | NPC1 308/4885MAPT 101/4885KMT2A 464/4885 |
| US-20060258691-A1 | Methods and compositions for improving cognition | PSEN1, PSEN2, APP | NPC1 256/4885MAPT 9/4885KMT2A 426/4885 |
| US-20070049608-A1 | Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use | DPYD, TYMP, PNKP | NPC1 3748/4885MAPT 1982/4885KMT2A 4307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.